Neurology Today in 5  By  cover art

Neurology Today in 5

By: American Academy of Neurology
  • Summary

  • Joseph E. Safdieh, MD, FAAN, Editor-in-Chief of Neurology Today highlights the most noteworthy and newsworthy neurology stories in the issue.
    2024
    Show more Show less
Episodes
  • Generative AI for personal statements, Match Day and neurology, AHS statement on CGRP-targeting therapies
    May 2 2024

    Neurology Today Editor-in-Chief Joseph E. Safdieh, MD, FAAN, highlights new articles that discuss program directors’ response to the use of generative AI for personal statements, the good news for neurology based on the 2024 Match Day, and the AHS statement on CGRP-targeting therapies as a game changer for migraine treatment.

    Show more Show less
    5 mins
  • ME/CFS and long COVID; negative outcomes for ALS drug; donanemab
    Apr 18 2024

    Neurology Today Editor-in-Chief Joseph E. Safdieh,MD, FAAN, highlights new research that explores an association between myalgic encephalomyelitis/chronic fatigue and long COVID; negative phase 3 findings on AMX0035 for ALS, and the pending approval of donanemab for Alzheimer’s disease.

    Show more Show less
    5 mins
  • BTK inhibitors for MS, lecanemab, neurologic adverse effects and COVID vaccine
    Apr 4 2024

    Neurology Today Editor-in-Chief Joseph E. Safdieh,MD, FAAN, highlights new research that casts doubt on the future of BTK inhibitors for MS, an assessment of the cost-effectiveness of lecanemab, and findings that COVID vaccines are not significantly associated with adverse neurologic events.

    Show more Show less
    4 mins

What listeners say about Neurology Today in 5

Average customer ratings

Reviews - Please select the tabs below to change the source of reviews.